RTI Surgical (NASDAQ:RTIX) and COLLPLANT HOLDI/S (NASDAQ:CLGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

68.9% of RTI Surgical shares are held by institutional investors. 4.9% of RTI Surgical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for RTI Surgical and COLLPLANT HOLDI/S, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RTI Surgical 0 0 1 0 3.00
COLLPLANT HOLDI/S 0 0 0 0 N/A

Valuation & Earnings

This table compares RTI Surgical and COLLPLANT HOLDI/S’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RTI Surgical $279.56 million 1.00 $6.27 million $0.05 87.80
COLLPLANT HOLDI/S $480,000.00 39.19 -$6.02 million ($2.26) -2.43

RTI Surgical has higher revenue and earnings than COLLPLANT HOLDI/S. COLLPLANT HOLDI/S is trading at a lower price-to-earnings ratio than RTI Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares RTI Surgical and COLLPLANT HOLDI/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RTI Surgical -3.91% 4.04% 2.07%
COLLPLANT HOLDI/S -552.97% -80.17% -41.81%

Summary

RTI Surgical beats COLLPLANT HOLDI/S on 10 of the 11 factors compared between the two stocks.

RTI Surgical Company Profile

RTI Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes. The company's implants are used in the fields of sports medicine, general surgery, spine, orthopedic, trauma, and cardiothoracic procedures to repair and promote the natural healing of human bone and other human tissues; and to enhance surgical outcomes. It markets its products through its direct distribution force, as well as through a network of independent distributors. The company was formerly known as RTI Biologics, Inc. and changed its name to RTI Surgical, Inc. in July 2013. RTI Surgical, Inc. was founded in 1997 and is headquartered in Alachua, Florida.

COLLPLANT HOLDI/S Company Profile

CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.

Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.